During the past decade, Michigan Head Pain and Neurological Institute conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 43 clinical trials were completed, i.e. on average, 84.3% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 22 clinical trials were completed. i.e. 95.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Michigan Head Pain and Neurological Institute" #1 sponsor was "Pfizer" with 13 trials, followed by "Eli Lilly and Company" with 10 trials sponsored, "H. Lundbeck A/S" with 7 trials sponsored, "Allergan" with 5 trials sponsored and "Amgen" with 5 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Michigan Head Pain and Neurological Institute" #1 collaborator was "Novartis" with 3 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Alder Biopharmaceuticals, Inc." with 1 trials as a collaborator, "Clinvest" with 1 trials as a collaborator and "Synteract, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Michigan Head Pain and Neurological Institute" are "Migraine" (25 trials), "Migraine Headache" (5 trials), "Migraine, With or Without Aura" (5 trials), "Chronic Cluster Headache" (4 trials) and "Episodic Migraine" (4 trials). Many other conditions were trialed in "Michigan Head Pain and Neurological Institute" in a lesser frequency.

Most popular intervention types in "Michigan Head Pain and Neurological Institute" are "Drug" (72 trials), "Device" (10 trials), "Biological" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "Eptinezumab" (7 trials), "Galcanezumab" (7 trials), "Rimegepant" (6 trials) and "placebo" (5 trials). Other intervention names were less common.

The vast majority of trials in "Michigan Head Pain and Neurological Institute" are 82 trials for "All" genders.

Currently, there are NaN active trials in "Michigan Head Pain and Neurological Institute". undefined are not yet recruiting, 10 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 63 completed trials in Michigan Head Pain and Neurological Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Michigan Head Pain and Neurological Institute, 4 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 5 trials that are defined as “Not Applicable".